Regeneron (REGN) · Biotechnology
Regeneron Q2 2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Regeneron's EYLEA HD became the larger U.S. eye franchise product while Dupixent and Libtayo kept growing, even as the fianlimab melanoma trial missed its primary endpoint.
EYLEA HD overtook EYLEA for the first time and now makes up about 60% of U.S. franchise net sales, up from 34% a year ago, helped by an FDA-approved dosing interval of up to every 20 weeks. Dupixent added approval in chronic spontaneous urticaria for children aged 2 to 11. Libtayo grew on higher demand, and Lynozyfic recorded its first full quarter of sales.
Management is steering toward a broader pipeline of about 50 clinical candidates, with cemdisiran in gMG under FDA priority review (target action date November 2026), new Factor XI antibody trials in peripheral artery disease, and external deals such as Parabilis. The tension is concentration and execution: the fianlimab Phase 3 melanoma miss weakens a key oncology combination, and EYLEA faces competition and biosimilar risk.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗, Investing.com ↗.
Key numbers
- Total revenues · GAAP
- $4.3B
- Net income · GAAP
- $1.3B
- Diluted EPS · GAAP
- $12.23
- Diluted EPS · non-GAAP
- $14.29
- Income from operations · GAAP
- 1.3B
- Gross margin on net product sales · GAAP
- 78%
- Free cash flow, six months · non-GAAP
- $1.4B
up 17% from a year ago
down 7% from a year ago
down 5% from a year ago
up 11% from a year ago
down from 83% a year ago
down from $1,741.2 million a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Dupixent global net sales (recorded by Sanofi) | $6.0B | up 38% |
| EYLEA HD U.S. net sales | $596.0M | up 52% |
| EYLEA U.S. net sales | 412.0M | down 45% |
| Libtayo global net sales | 489.0M | up 30% |
| Lynozyfic global net sales | 17.0M | |
| Sanofi collaboration revenue | 2.2B | up 51% |
Where each number comes from
- Total revenues: “Financial Highlights ($ in millions, except per share data) | Q2 2026 | Q2 2025 | % Change Total revenues | $4,291 | $3,676 | 17%”
- Net income: “Total revenues | $4,291 | $3,676 | 17% GAAP net income | $1,297 | $1,392 | (7 | %)”
- Diluted EPS: “GAAP net income per share - diluted | $12.23 | $12.81 | (5 | %) Non-GAAP net income(a) | $1,543 | $1,424 | 8%”
- Diluted EPS: “Non-GAAP net income per share - diluted(a) | $14.29 | $12.89 | 11%”
- Income from operations: “2,997.2 | 2,596.1 | 5,959.7 | 5,033.1 Income from operations | 1,293.5 | 1,079.5 | 1,936.4 | 1,671.2 Other income (expense):”
- Gross margin on net product sales: “Gross margin on net product sales(b) | 78% | 83% | 87% | 86%”
- Free cash flow, six months: “Net cash provided by operating activities | $1,891.9 | $2,189.5 Capital expenditures | (470.8) | (448.3) Free cash flow | $1,421.1 | $1,741.2”
- Dupixent global net sales (recorded by Sanofi): “Dupixent(a) | $4,561.1 | $1,437.1 | $5,998.2 | $3,205.0 | $1,139.6 | $4,344.6 | 38%”
- EYLEA HD U.S. net sales: “EYLEA HD - U.S. | $596 | $393 | 52% EYLEA® - U.S. | 412 | 754 | (45 | %)”
- EYLEA U.S. net sales: “EYLEA HD - U.S. | $596 | $393 | 52% EYLEA® - U.S. | 412 | 754 | (45 | %)”
- Libtayo global net sales: “Total Libtayo - Global | 489 | 377 | 30% Praluent® - U.S. | 75 | 66 | 14%”
- Lynozyfic global net sales: “Lynozyfic® - Global | 17 | — | ** Total net product sales | 1,642 | 1,631 | 1%”
- Sanofi collaboration revenue: “Collaboration revenue: Sanofi | 2,174 | 1,444 | 51% Bayer | 276 | 415 | (33 | %)”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $4.3B | +16.7% | +19.0% |
| Operating income | $1.3B | +19.8% | +101.2% |
| Net income | $1.3B | −6.8% | +78.3% |
| Diluted EPS | $12.23 | −4.5% | +81.2% |
| Free cash flow | $572.8M | −38.1% | −32.5% |
| Operating margin | 30.1% | +0.7 pts | +12.3 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| GAAP R&D | full year 2026 | $6.500–$6.635 billion |
| GAAP SG&A | full year 2026 | $2.830–$2.960 billion |
| GAAP gross margin on net product sales | full year 2026 | 78%–79% |
| Non-GAAP gross margin on net product sales | full year 2026 | 84%–85% |
| Capital expenditures | full year 2026 | $1.030–$1.100 billion |
| GAAP effective tax rate | full year 2026 | 13%–14% |
| Non-GAAP effective tax rate | full year 2026 | 14%–15% |
Key takeaways
EYLEA HD now outsells EYLEA in the U.S.
EYLEA HD net sales rose on higher volumes from increased demand, while EYLEA volumes fell on competition and patient transition to HD. The franchise is shifting to the newer, longer-interval product.
EYLEA HD gets dosing up to every 20 weeks
The FDA approved extended intervals for wAMD and DME after one year of successful response. Fewer injection visits could strengthen its position against competing eye treatments.
Dupixent keeps expanding into new patient groups
Dupixent was approved by the FDA and European Commission for CSU in children aged 2 to 11 who remain symptomatic on antihistamines. This widens the eligible population for the product Sanofi sells and Regeneron shares profits on.
Fianlimab melanoma trial missed its primary endpoint
The Phase 3 trial of fianlimab with cemiplimab did not reach statistical significance on progression-free survival versus pembrolizumab. This is a setback for the LAG-3 oncology strategy, leaving Libtayo as the oncology anchor.
Pipeline broadens with cemdisiran, Factor XI and deals
Cemdisiran is under FDA priority review for gMG and accepted by the EMA. Regeneron also started Phase 3 PAD studies for two Factor XI antibodies and partnered with Parabilis Medicines on peptide-based candidates.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $3.8B * |
| Q1 2025 | $3.0B |
| Q2 2025 | $3.7B |
| Q3 2025 | $3.8B |
| Q4 2025 | $3.9B * |
| Q1 2026 | $3.6B |
| Q2 2026 | $4.3B |
| Q3 2026 | $5.1B |
Data
| Q1 2025 | $7.27 |
| Q2 2025 | $12.81 |
| Q3 2025 | $13.62 |
| Q1 2026 | $6.75 |
| Q2 2026 | $12.23 |
| Q3 2026 | $18.45 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 26.1% |
| Q1 2025 | 19.5% |
| Q2 2025 | 29.4% |
| Q3 2025 | 27.3% |
| Q4 2025 | 22.7% |
| Q1 2026 | 17.8% |
| Q2 2026 | 30.1% |
| Q3 2026 | 40.0% |
Data
| Q4 2024 | $1.1B |
| Q1 2025 | $815.8M |
| Q2 2025 | $925.4M |
| Q3 2025 | $1.4B |
| Q4 2025 | $922.0M |
| Q1 2026 | $848.3M |
| Q2 2026 | $572.8M |
| Q3 2026 | $1.5B |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What happened with EYLEA HD this quarter?
EYLEA HD U.S. net sales grew 52% to $596 million on higher demand, and the FDA approved dosing intervals of up to every 20 weeks for wAMD and DME. It now accounts for about 60% of U.S. franchise net sales, up from 34% a year earlier.
What is the status of the fianlimab melanoma program?
In May 2026 Regeneron reported that the Phase 3 first-line melanoma trial of fianlimab plus cemiplimab did not reach statistical significance on progression-free survival versus pembrolizumab monotherapy.
What regulatory milestones are coming for cemdisiran?
The FDA accepted the gMG application under priority review with a target action date in November 2026, following use of a Priority Review Voucher. A European Commission decision is expected in the second half of 2027.
How is Regeneron expanding its pipeline and manufacturing?
It has about 50 clinical candidates, a new Parabilis Medicines collaboration, and Phase 3 Factor XI antibody studies in peripheral artery disease. Its Saratoga Springs, New York facility, under construction, was selected for the FDA PreCheck Pilot Program, and bulk manufacturing at Limerick, Ireland returned to normal levels.
How is Regeneron's relationship with Sanofi changing?
The Sanofi Development Balance was fully repaid at the end of the quarter, so it no longer reduces collaboration revenue from the third quarter. Management also described early discussions with Sanofi on further collaboration opportunities.
Documents
SEC filing